Trial Information

Summary: A Multicenter Treatment Protocol for Compassionate Use of Ipilimumab (BMS-734016) Monotherapy in Subjects with Unresctable StageIII or Stage IV Melanoma

You have been asked to participate in this research study because you have malignant melanoma and you could not tolerate (had bad side effects from) previous treatment or you did not benefit from previous treatment   The purpose of this study is to give subjects like you an opportunity to receive treatment with an investigational compound called ipilimumab (also called MDX-010 or BMS-734016) which is not yet approved by the United Stated Food and Drug Administration (FDA).  The other purpose of this study is to collect safety information such as side effects and blood and other laboratory test abnormalities that might be caused by iplimumab.  This information will be reported by the sponsor to the FDA in support of possible approval of this drug in the near future. Your treatment on this study is expected to last for as long as you are benefiting from this drug and not having unmanageable side effects or until the drug is approved by the FDA.  After your treatment on this study is over, your medical condition will continue to be followed indefinitely.

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 2, 2008 at 2:51:06 PM